DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,000,091 | -98.8% | 4,031 | -98.8% | 0.00% | -98.9% |
Q2 2023 | $80,750,640 | +180.4% | 336,461 | +194.5% | 0.18% | +147.2% |
Q1 2023 | $28,797,082 | +2468.9% | 114,256 | +2533.2% | 0.07% | +2300.0% |
Q3 2022 | $1,121,000 | -62.2% | 4,339 | -62.9% | 0.00% | -70.0% |
Q2 2022 | $2,962,000 | -95.0% | 11,684 | -94.2% | 0.01% | -94.6% |
Q1 2022 | $59,034,000 | -37.9% | 201,257 | -30.4% | 0.19% | -42.8% |
Q4 2021 | $95,115,000 | +1010.1% | 289,094 | +805.5% | 0.32% | +692.7% |
Q2 2021 | $8,568,000 | -83.2% | 31,928 | -85.9% | 0.04% | -83.7% |
Q1 2021 | $50,973,000 | +385.6% | 226,464 | +379.3% | 0.25% | +332.8% |
Q4 2020 | $10,496,000 | -46.3% | 47,251 | -57.2% | 0.06% | -65.7% |
Q2 2020 | $19,534,000 | +182.2% | 110,470 | +120.9% | 0.17% | +106.1% |
Q1 2020 | $6,921,000 | -3.7% | 50,000 | 0.0% | 0.08% | +78.3% |
Q2 2019 | $7,187,000 | -47.6% | 50,000 | -51.9% | 0.05% | -49.5% |
Q1 2019 | $13,718,000 | +146.4% | 103,908 | +92.4% | 0.09% | +127.5% |
Q4 2018 | $5,568,000 | -75.7% | 54,000 | -74.4% | 0.04% | -61.5% |
Q3 2018 | $22,954,000 | +825.6% | 211,249 | +740.6% | 0.10% | +845.5% |
Q2 2018 | $2,480,000 | -68.1% | 25,131 | -68.4% | 0.01% | -65.6% |
Q1 2018 | $7,776,000 | +35.0% | 79,422 | +27.9% | 0.03% | +77.8% |
Q4 2017 | $5,762,000 | -92.3% | 62,077 | -92.9% | 0.02% | -93.9% |
Q3 2017 | $74,824,000 | +83.3% | 872,278 | +80.3% | 0.29% | +74.4% |
Q2 2017 | $40,819,000 | -30.6% | 483,690 | -29.7% | 0.17% | -38.7% |
Q1 2017 | $58,812,000 | +26.7% | 687,619 | +15.3% | 0.27% | +10.0% |
Q4 2016 | $46,403,000 | +476.8% | 596,139 | +480.8% | 0.25% | +429.8% |
Q3 2016 | $8,045,000 | +110.2% | 102,634 | +105.3% | 0.05% | +88.0% |
Q2 2016 | $3,827,000 | -94.9% | 50,000 | -93.7% | 0.02% | -94.4% |
Q1 2016 | $75,520,000 | +51.0% | 796,120 | +47.9% | 0.45% | +29.1% |
Q4 2015 | $50,008,000 | -21.5% | 538,412 | -28.0% | 0.35% | -26.2% |
Q3 2015 | $63,675,000 | +14.5% | 747,277 | +15.0% | 0.47% | +37.4% |
Q2 2015 | $55,634,000 | -8.2% | 650,009 | -8.9% | 0.34% | -30.2% |
Q1 2015 | $60,583,000 | +67.9% | 713,586 | +25.2% | 0.49% | -19.1% |
Q2 2013 | $36,074,000 | – | 569,894 | – | 0.61% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |